Cordyceps Militaris Capsules Trial Protocol for COPD Patients

A study protocol document outlines a double-blind, randomized, placebo-controlled clinical trial investigating Cordyceps militaris capsules for patients with mild-to-moderate stable COPD. The trial involves 160 participants aged 40-85 years, with a 24-week treatment period and a 24-week follow-up. The primary outcome is the change in post-bronchodilator FEV1, with secondary measures including other lung function parameters, exacerbation frequency, and quality-of-life questionnaires.

Use Cases

• Analyze clinical trial design and outcome measures for respiratory interventions based on the described primary and secondary endpoints.
• Study the application of traditional Chinese medicine in chronic disease management based on the trial's focus on Cordyceps militaris.
• Benchmark lung function measurement protocols in COPD research based on the described FEV1, FVC, and other spirometry metrics.

Strengths

• The protocol describes a multi-center, randomized, double-blind, placebo-controlled trial design, which is a rigorous standard for clinical research.
• Specific sample size (160 patients) and patient age range (40-85 years) are provided.
• Clear primary and multiple secondary outcome measures are defined, including lung function tests and patient-reported questionnaires.

Limitations

• The dataset is a 343.5 KB DOCX file containing a study protocol, not a structured dataset of trial results.
• Column-level documentation is absent; field semantics must be inferred from the protocol text after download.
• Row count is unknown, which may limit suitability assessment for data analysis.

Provenance

Source

Author Siqi Lin, uploaded to figshare.

Collection Method

Describes the methodology for a planned clinical trial.

Freshness

Last updated 2026-05-25 06:07:17; freshness should be verified.